Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice | Zendy

Simona Ferraro | Zendy; Chiara Trevisiol | Zendy; Massimo Gion | Zendy; Mauro Panteghini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice

Author(s) -

Simona Ferraro,

Chiara Trevisiol,

Massimo Gion,

Mauro Panteghini

Publication year - 2017

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2017.275263

Subject(s) - human chorionic gonadotropin , seminoma , medicine , germ cell tumors , andrology , gonadotropin , gynecology , hormone , chemotherapy

Clinical practice guidelines recommend the measurement of human chorionic gonadotropin (hCG) and/or hCGβ in serum for management of testicular germ cell tumors (GCTs). These guidelines, however, disregard relevant biochemical information on hCG variants to be detected for oncological application. We set out to provide a critical review of the clinical evidence together with a characterization of the selectivity of currently marketed hCG immunoassays, identifying assays suitable for management of GCTs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research